🇺🇸 Ezetimibe + Simvastatin in United States
872 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 872
Most-reported reactions
- Diarrhoea — 126 reports (14.45%)
- Acute Kidney Injury — 125 reports (14.33%)
- Fatigue — 102 reports (11.7%)
- Dyspnoea — 87 reports (9.98%)
- Rhabdomyolysis — 80 reports (9.17%)
- Myalgia — 79 reports (9.06%)
- Drug Interaction — 78 reports (8.94%)
- Dizziness — 69 reports (7.91%)
- Nausea — 67 reports (7.68%)
- Asthenia — 59 reports (6.77%)
Other Cardiovascular approved in United States
Frequently asked questions
Is Ezetimibe + Simvastatin approved in United States?
Ezetimibe + Simvastatin does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Ezetimibe + Simvastatin in United States?
Organon and Co is the originator. The local marketing authorisation holder may differ — check the official source linked above.